<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01453361</url>
  </required_header>
  <id_info>
    <org_study_id>CL-PTL 114</org_study_id>
    <nct_id>NCT01453361</nct_id>
  </id_info>
  <brief_title>Phase II FANG™ in Advanced Melanoma</brief_title>
  <official_title>Phase II Trial of FANG™ Autologous Tumor Cell Vaccine in Advanced Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gradalis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gradalis, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preliminary studies with a variety of vaccines suggest target accessibility (potential
      immunogenicity) in a variety of solid tumors to immune directed approaches. In an effort to
      overcome limitations of immunostimulatory cancer vaccines, the investigators have designed a
      novel autologous vaccine to address inability to fully identify cancer associated antigens,
      antigen recognition by the immune system (i.e. antigen to immunogen), effector potency, and
      cancer-induced resistance. In an effort to overcome limitations of immunostimulatory cancer
      vaccines, the investigators designed a novel dual-modulatory autologous whole cell vaccine,
      Vigil™ (bi-shRNA furin and GMCSF Autologous Tumor Cell Vaccine), incorporating the rhGMCSF
      (recombinant human GMCSF) transgene and the bifunctional shRNAfurin (to block proprotein
      conversion to active TGFb1 and b2) to 1) address the inability to fully identify cancer
      associated antigens, 2) effect antigen recognition by the immune system (i.e. antigen to
      immunogen), 3) enhance effector potency, and 4) subvert endogenous cancer-induced immune
      resistance. The investigators have also completed the Phase I assessment of Vigil™ vaccine in
      27 advanced solid tumor patients (1.0 x 10e7 or 2.5 x 10e7 cells/injection/month for a
      maximum of 12 vaccinations) who have not experienced any significant adverse effects
      following 131 vaccinations, including 4 patients with melanoma. Plasmid functionality, immune
      biomarker response, and preliminary evidence of anticancer activity have been observed. This
      is a Phase II study of intradermal autologous Vigil™ cancer vaccine (1.0 x 10e7
      cells/injection; maximum of 12 vaccinations) in patients with stages IIIc and IV melanoma
      with biopsy accessible lesions to document blood and intratumoral immune responses and assess
      correlation with survival.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business Decision to pursue other indications
  </why_stopped>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">March 22, 2016</completion_date>
  <primary_completion_date type="Actual">March 22, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Enzyme-Linked ImmunoSorbent Spot (ELISPOT)</measure>
    <time_frame>Baseline, End of Treatment (30 days after last dose) up to 12 months</time_frame>
    <description>To determine if subjects will have a positive (defined as &gt;10 ELISPOTS from baseline) immune response to Vigil. Blood was collected to compare ELISPOT results from baseline until EOT (30 days after last dose).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Alive Subjects</measure>
    <time_frame>3 years</time_frame>
    <description>The survival status in patients with stages IIIc and IV melanoma treated with Vigil™ vaccine was determined by following these patients up to 3 years.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Advanced Melanoma</condition>
  <arm_group>
    <arm_group_label>Vigil™ Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous Vigil™ vaccine will be supplied by Gradalis, Inc. Patients will receive 1 x 10e7 cells via intradermal injection one day each month for a minimum maximum of 12 doses as long as subject is clinically stable.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vigil™ Vaccine</intervention_name>
    <arm_group_label>Vigil™ Vaccine</arm_group_label>
    <other_name>formerly known as FANG™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed Stages IIIc and IV melanoma.

          2. Has been informed of all alternative ≥ second-line therapies that are the current
             standard of care. If no conventional frontline therapy indicated or acceptable by
             patient, patient may participate after review by sponsor.

          3. Clinically (medically) indicated procedure (i.e. biopsy of lesions of recurrent
             disease, palliative management via resection, thoracentesis, etc.) to collect viable
             tumor in sufficient quantity (&quot;golf ball size&quot; estimated weight ~ 30 grams, pleural
             and/or ascites fluid estimated volume ≥ 500mL) for vaccine processing.

          4. Recovered to ≤ Grade 1 (excluding alopecia) from all clinically relevant toxicities
             related to prior therapies.

          5. Patients will be allowed to participate following single prior CNS treatment with
             stereotactic radiotherapy whole brain irradiation and stable without steroid
             requirement for ≥2 months or following ≥2 prior CNS treatments with stereotactic
             radiotherapy whole brain irradiation and stable without steroid requirement for ≥4
             months.

          6. Patients must be off all &quot;statin&quot; drugs for ≥ 2 weeks prior to initiation of therapy.

          7. Age ≥18 years.

          8. ECOG performance status (PS) 0-1.

          9. Estimated &gt;4 month survival probability.

         10. Normal organ and marrow function as defined below:

             Absolute granulocyte count ≥1,500/mm3 Absolute lymphocyte count ≥500/mm3 Platelets
             ≥100,000/mm3 Total bilirubin ≤2 mg/dL AST(SGOT)/ALT(SGPT) ≤2x institutional upper
             limit of normal Creatinine &lt;1.5 mg/dL

         11. Ability to understand and the willingness to sign a written informed consent document.

         12. Negative pregnancy test.

        Exclusion Criteria:

          1. Surgery involving general anesthesia, chemotherapy, radiotherapy, steroid therapy, or
             immunotherapy within 4 weeks prior to entering the study. Collection of lumenal tissue
             must be avoided.

          2. Patient must not have received any other investigational agents within 30 days prior
             to study entry.

          3. Patients with known active or symptomatic brain metastases.

          4. Patients with compromised pulmonary disease.

          5. Short term (&lt;30 days) concurrent systemic steroids ≤ 0.25 mg/kg prednisone per day
             (maximum 7.5 mg/day) and bronchodilators (inhaled steroids) are permitted; other
             steroid regimens and/or immunosuppressives are excluded. Patients requiring steroids
             following previous CNS radiation for metastatic disease are excluded.

          6. Prior splenectomy.

          7. Prior malignancy (excluding nonmelanoma carcinomas of the skin) unless in remission
             for 2 years.

          8. Kaposi's Sarcoma.

          9. Uncontrolled intercurrent illness including, but not limited to ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

         10. Patients who are pregnant or nursing.

         11. Patients with known HIV.

         12. Patients with chronic Hepatitis B and C infection.

         13. Patients with uncontrolled autoimmune diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Minal Barve, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mary Crowley Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Centers</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.oatext.com/pdf/BGG-1-116.pdf</url>
    <description>Follow-up of bi-shRNAfurin /GM-CSF Engineered Autologous Tumor Cell (EATC) Immunotherapy Vigil in patients with advanced melanoma</description>
  </link>
  <reference>
    <citation>Olivares J, Kumar P, Yu Y, Maples PB, Senzer N, Bedell C, Barve M, Tong A, Pappen BO, Kuhn J, Magee M, Wallraven G, Nemunaitis J. Phase I trial of TGF-beta 2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine. Clin Cancer Res. 2011 Jan 1;17(1):183-92. doi: 10.1158/1078-0432.CCR-10-2195.</citation>
    <PMID>21208907</PMID>
  </reference>
  <reference>
    <citation>Maples PB, Kumar P, Yu Y, Wang Z, Jay CM, Pappen BO, Rao DD, Kuhn J, Nemunaitis J, Senzer N: FANG Vaccine: Autologous Tumor Cell Vaccine Genetically Modified to Express GM-CSF and Block Production of Furin. BioProcessing Journal 2010; 8(4):4-14.</citation>
  </reference>
  <reference>
    <citation>Senzer N, Barve M, Kuhn J, Melnyk A, Beitsch P, Lazar M, Lifshitz S, Magee M, Oh J, Mill SW, Bedell C, Higgs C, Kumar P, Yu Y, Norvell F, Phalon C, Taquet N, Rao DD, Wang Z, Jay CM, Pappen BO, Wallraven G, Brunicardi FC, Shanahan DM, Maples PB, Nemunaitis J. Phase I trial of &quot;bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell&quot; vaccine (FANG) in advanced cancer. Mol Ther. 2012 Mar;20(3):679-86. doi: 10.1038/mt.2011.269. Epub 2011 Dec 20.</citation>
    <PMID>22186789</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2011</study_first_submitted>
  <study_first_submitted_qc>October 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2011</study_first_posted>
  <results_first_submitted>February 15, 2018</results_first_submitted>
  <results_first_submitted_qc>May 8, 2018</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 10, 2018</results_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FANG</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Vigil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Modafinil</mesh_term>
    <mesh_term>Armodafinil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study recruited patients with Stages IIIc and IV melanoma.</recruitment_details>
      <pre_assignment_details>18 were enrolled but 10 screen-failed so only 8 proceeded with the single group assignment (Vigil treatment).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vigil™ Vaccine</title>
          <description>Autologous Vigil™ vaccine will be supplied by Gradalis, Inc. Patients will receive 1 x 10e7 cells via intradermal injection one day each month for a minimum maximum of 12 doses as long as subject is clinically stable.
Vigil™ Vaccine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen-Failures</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vigil™ Vaccine</title>
          <description>Autologous Vigil™ vaccine will be supplied by Gradalis, Inc. Patients will receive 1 x 10e7 cells via intradermal injection one day each month for a minimum maximum of 12 doses as long as subject is clinically stable.
Vigil™ Vaccine</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <title>0-15 Years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>16-64 Years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>65 and Older Years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White/Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black/African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Enzyme-Linked ImmunoSorbent Spot (ELISPOT)</title>
        <description>To determine if subjects will have a positive (defined as &gt;10 ELISPOTS from baseline) immune response to Vigil. Blood was collected to compare ELISPOT results from baseline until EOT (30 days after last dose).</description>
        <time_frame>Baseline, End of Treatment (30 days after last dose) up to 12 months</time_frame>
        <population>18 subjects were consented but only 8 subjects were administered Vigil treatment (10 screen-failed). 7 completed treatment (ELISPOT done) while 1 subject died soon after baseline (ELISPOT not done). After 12 months, 7 subjects had positive ELISPOT response. Statistical analysis was not done. This study was terminated.</population>
        <group_list>
          <group group_id="O1">
            <title>Vigil™ Vaccine</title>
            <description>Autologous Vigil™ vaccine will be supplied by Gradalis, Inc. Patients will receive 1 x 10e7 cells via intradermal injection one day each month for a minimum maximum of 12 doses as long as subject is clinically stable.
Vigil™ Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Enzyme-Linked ImmunoSorbent Spot (ELISPOT)</title>
          <description>To determine if subjects will have a positive (defined as &gt;10 ELISPOTS from baseline) immune response to Vigil. Blood was collected to compare ELISPOT results from baseline until EOT (30 days after last dose).</description>
          <population>18 subjects were consented but only 8 subjects were administered Vigil treatment (10 screen-failed). 7 completed treatment (ELISPOT done) while 1 subject died soon after baseline (ELISPOT not done). After 12 months, 7 subjects had positive ELISPOT response. Statistical analysis was not done. This study was terminated.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ELISPOT Positive After 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ELISPOT Negative After 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Done/Died immediately after Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Done/Screen-Failed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Alive Subjects</title>
        <description>The survival status in patients with stages IIIc and IV melanoma treated with Vigil™ vaccine was determined by following these patients up to 3 years.</description>
        <time_frame>3 years</time_frame>
        <population>18 subjects were consented but only 8 were administered Vigil treatment (10 screen-failed). These 8 subjects were followed for survival up to 3 years after Vigil treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Vigil™ Vaccine</title>
            <description>Autologous Vigil™ vaccine will be supplied by Gradalis, Inc. Patients will receive 1 x 10e7 cells via intradermal injection one day each month for a minimum maximum of 12 doses as long as subject is clinically stable.
Vigil™ Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Alive Subjects</title>
          <description>The survival status in patients with stages IIIc and IV melanoma treated with Vigil™ vaccine was determined by following these patients up to 3 years.</description>
          <population>18 subjects were consented but only 8 were administered Vigil treatment (10 screen-failed). These 8 subjects were followed for survival up to 3 years after Vigil treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alive Subjects After 3 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dead Subjects After 3 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screen-Failed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Vigil™ Vaccine</title>
          <description>Autologous Vigil™ vaccine will be supplied by Gradalis, Inc. Patients will receive 1 x 10e7 cells via intradermal injection one day each month for a minimum maximum of 12 doses as long as subject is clinically stable.
Vigil™ Vaccine</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Hernia</sub_title>
                <description>Incarcerated Abdominal Hernia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Soft Tissue Infection</sub_title>
                <description>Infection of Left Great Toe</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumor Pain</sub_title>
                <description>Sacral Nerve Compression secondary to Metastatic Melanoma</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Ulceration</sub_title>
                <description>Hemorrhage from tumor nodule</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Reaction</sub_title>
                <counts group_id="E1" events="9" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Trials</name_or_title>
      <organization>Gradalis, Inc.</organization>
      <phone>2144428124</phone>
      <email>info@gradalisinc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

